PR91160

TIANJIN, China, July 17, 2021 /PRNewswire=KYODO JBN/--

SINOMED, a leading international medical device company, announced the first

commercial implantation of the HT Supreme® Drug-Eluting Stent (DES) at

University Hospital Galway in partnership with the National University of

Ireland Galway (NUI Galway), marking the start of the European launch. The

procedure was successfully performed by Professor Faisal Sharif, Professor of

Translational Cardiovascular Medicine and Innovation at NUI Galway and

Consultant Interventional Cardiologist at Galway University Hospitals.  

Professor Sharif said "We are delighted to implant the HT Supreme stent from

SINOMED at University Hospital Galway in partnership with National University

of Ireland Galway. Early indications show the device deliverability to be good

and the novel stent technology offers faster stent endothelialisation, which

will potentially reduce the need for aggressive anti-platelet treatment.

Reducing the need for multiple anti-platelet treatment is an important issue

especially with an aging population and multiple co-morbidities of patients who

require coronary stenting."

The healing-targeted HT Supreme DES was approved for the treatment of patients

with narrowing or blockages to their coronary arteries.  This new device gives

clinicians an additional choice of a device that is tailored to help patients

accelerate their wound-healing process and restore their naturally protective

vessel function after a stenting procedure.

"The HT Supreme represents a different DES technology by offering a solution

specifically designed to encourage rapid healing following implantation," said

Alain Aimonetti, Chief Commercial Officer, Sales, Marketing and Clinical

Affairs.  "This product launch is a significant landmark for SINOMED Europe as

we begin the commercial phase of our operations. Additionally, we will continue

our clinical commitment with further investments in the HT Supreme's robust

clinical program."    

"We are honored to be the first Chinese company to partner with the CORRIB

Research Centre for Advanced Imaging and Core Laboratory for the PIONEER IV

study," said Dr. Jianhua Sun, PhD., Chairman and Chief Executive Officer of

SINOMED.  "Based on previous clinical experience, the HT Supreme has been

documented to be safe and effective.  This new study shortens the dual

antiplatelet medication for all patients, which will reduce the risk of

bleeding, and assess a new method to further improve the quality of treating

patients."

Prof. Sharif is one of four global Principal Investigators of the PIONEER IV

trial , which is a prospective, randomised trial that will take place in 30

hospitals across Europe, enrolling 2,540 patients suffering from any type of

coronary artery disease, including acute heart attack, chronic complaints or

vessel narrowing.  Patients eligible will undergo a non-invasive physiological

vessel selection process to determine which vessel requires stenting.  All

patients enrolled into the trial will use the HT Supreme DES and be required to

take one month dual-antiplatelet therapy after stenting.

The PIONEER IV is an investigator driven trial sponsored by NUI Galway and is

centrally coordinated by the University's CORRIB Research Centre for Advanced

Imaging and Core Laboratory, led by Professor Patrick W. Serruys, Established

Professor of Interventional Medicine and Innovation, and Professor William

Wijns, Science Foundation Ireland Professor of Interventional Cardiology.

More information on the PIONEER IV study is available at

www.clinicaltrials.gov, identifier: NCT04923191.

About the HT Supreme Drug-Eluting Stent

The HT Supreme represents a novel class of stents that highlights the

importance of early, timely healing.  Through patented designs and proprietary

processes, the HT Supreme is tailored to help patients accelerate their

wound-healing process and restore their naturally protective vessel function.  

About SINOMED

SINOMED is a global medical device company engaged in research, development,

production, and commercial distribution of interventional devices. We are

focused on developing breakthrough technologies to target unmet clinical needs

in the interventional treatment of coronary, neurovascular and structural heart

disease. Our mission is to expose more patients to the benefits of our medical

innovations, increasing patient longevity and quality of life.  For more

information visit www.sinomed.com.

About National University of Ireland Galway (NUI Galway)

Established in 1845, NUI Galway is a bilingual university comprised of four

colleges, 19 schools, five research institutes, 19,070 students, 3,308

international students, 2,200 staff, research collaborations with 3,267

international institutions in 114 countries, 110,000 alumni, while 98% of

graduates are in employment or further study within six months.

For more information visit www.nuigalway.ie

Contact:

SINOMED B.V

Cindy Zheng

Wilhelminakade 173

3072AP Rotterdam

The Netherlands

T:  +31-10-307-6295

E:  cindy.zheng@sinomed-eu.com

Photo- https://mma.prnewswire.com/media/1595061/SINOMED_Image.jpg

Logo: https://mma.prnewswire.com/media/1333950/SINOMED_Logo.jpg